Skip Navigation


Rheumatology Advance Access originally published online on February 10, 2005
Rheumatology 2005 44(5):695-696; doi:10.1093/rheumatology/keh562
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
44/5/695    most recent
keh562v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chevillotte-Maillard, H.
Right arrow Articles by Maillefert, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chevillotte-Maillard, H.
Right arrow Articles by Maillefert, J. F.
Related Collections
Right arrow Spondylarthropathies
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

LETTER TO THE EDITOR

Survival and safety of treatment with infliximab in the elderly population

H. Chevillotte-Maillard1, P. Ornetti1, R. Mistrih1, C. Sidot2, J. Dupuis3, J.-A. Dellas4, C. Tavernier1 and J. F. Maillefert1,5

1 Department of Rheumatology, Dijon University Hospital, Dijon, 2 Department of Medicine and Rheumatology, J. Bouveri Hospital, Montceau les Mines, 3 Department of Rheumatology, Hôtel Dieu Hospital, Le Creusot, 4 Department of Rheumatology, G. Ramon Hospital, Sens and 5 INSERM/ERIT-M 0207, University of Burgundy, Dijon, France

Correspondence to: J. F. Maillefert, Department of Rheumatology, Hôpital Général, 3 rue du Fb Raines, 21000 Dijon, France. E-mail: jean-francis.maillefert@chu-dijon.fr

The first 10% of the full text of this article appears below.

SIR, Anti-tumour necrosis factor {alpha} (TNF-{alpha}) agents, such as infliximab, represent a major advance in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) treatment. Infliximab is usually well tolerated but has some potential adverse effects, particularly infections [1–6]. The ageing process induces a decline in the function and control of the immune system. Thus, the prevalence of adverse effects of anti-TNF-{alpha} agents, and particularly of infections, might be increased in the elderly population. However, being elderly does not appear in most recommendations regarding the prescription . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?